{"id":2041,"date":"2020-07-17T12:33:11","date_gmt":"2020-07-16T23:33:11","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=2041"},"modified":"2020-07-17T12:33:11","modified_gmt":"2020-07-16T23:33:11","slug":"dr-ghia-on-the-shift-from-chemotherapy-to-novel-agents-in-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=2041","title":{"rendered":"Dr. Ghia on the Shift From Chemotherapy to Novel Agents in CLL"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Dr. Ghia on the Shift From Chemotherapy to Novel Agents in CLL<\/h1>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by Onc Live<\/a><\/p>\n

 <\/p>\n

\n
\n
\n
\n
\n

Paolo Ghia, MD, PhD, a professor of Medical Oncology and the director of the Strategic Research Program on CLL and the B Cell Neoplasia Unit at Vita-Salute San Raffaele University, discusses\u00a0how use the of\u00a0chemotherapy is\u00a0decreasing in favor of\u00a0novel agents in chronic lymphocytic leukemia (CLL).<\/p>\n

Chemotherapy regimens and chemoimmunotherapy treatment approaches\u00a0are\u00a0fading out of the treatment algorithm of CLL, says Ghia. This shift will be seen in the updated ASCO guidelines, where chemoimmunotherapy only remains an option\u00a0for\u00a0patients who do not have access to the novel therapies that are\u00a0currently\u00a0available in some countries and regions.<\/p>\n

Not everyone has the same accessibility, but for the patients who do, particularly in the first-line setting, most of them experience a benefit from novel therapies. Even in the relapsed\/refractory setting, the\u00a0percentage\u00a0of patients who benefit from chemoimmunotherapy is reducing with time, concludes Ghia.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents in chronic lymphocytic leukemia<\/p>\n","protected":false},"author":1,"featured_media":2042,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-2041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/07\/Dr-Ghia.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/2041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2041"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/2041\/revisions"}],"predecessor-version":[{"id":2043,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/2041\/revisions\/2043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/2042"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}